^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Excerpt:
Three PRs (two confirmed and one unconfirmed) were seen in patients with urothelial cancer who had received more than four lines of prior treatment, including a patient with FGFR3-TACC3 who stayed on treatment (at 9 mg daily) for about 10 months, a patient with FGFR2-BICC1/FGFR2-CASP7 (FGFR2-BICC1 was more frequent than FGFR2-CASP7, per polymerase chain reaction assay) who continued to be on study drug (9 mg daily) at 12 months, and another patient with FGFR3-TACC3 who continued to be on the study drug (12-mg intermittent dose) at 3 months.
DOI:
10.1200/JCO.2014.60.7341
